Biocon and Handok link to commercialise Liraglutide in South Korea

Biocon has entered an exclusive licence and supply agreement with Handok to commercialise synthetic Liraglutide in South Korea.

May 25, 2024 - 04:00

Biocon and Handok link to commercialise Liraglutide in South Korea

Biocon has entered an exclusive licence and supply agreement with Handok to commercialise synthetic Liraglutide in South Korea.

Read the original article

Tags:

Previous Article

EC approves Celltrion’s Omlyclo for allergic conditions

Magazine: Lula’s progress plan for Brazil: a year on

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Major biomedical research funder Wellcome Trust names Røttingen as its new CEO

Major biomedical research funder Wellcome Trust names R...

Oct 12, 2023

Upstream Bio raises funds to advance clinical development of UPB-101

Upstream Bio raises funds to advance clinical developme...

Jun 9, 2023

China NMPA grants approval for GenFleet’s fulzerasib to treat lung cancer

China NMPA grants approval for GenFleet’s fulzerasib to...

Aug 27, 2024